出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/05/19 03:27:54」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • China type 2 diabetes treatment status survey of treatment pattern of oral drugs users 2.
  • Ji L1, Lu J, Weng J, Jia W, Tian H, Zhu D, Xing X, Guo L.
  • Journal of diabetes.J Diabetes.2015 Mar;7(2):166-73. doi: 10.1111/1753-0407.12165. Epub 2014 Aug 7.
  • BACKGROUND: The aim of the present study was to investigate the current status of oral anti-diabetic drug (OAD) therapy in patients with type 2 diabetes and influencing factors in a real-world setting in China.METHODS: A total of 9872 outpatients with type 2 diabetes, who had received OADs (monother
  • PMID 24809622
  • Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation.
  • Krishan S1, Richardson DR2, Sahni S2.
  • Molecular pharmacology.Mol Pharmacol.2015 Mar;87(3):363-77. doi: 10.1124/mol.114.095810. Epub 2014 Nov 24.
  • Adenosine monophosphate-activated protein kinase (AMPK) is a cellular energy sensor, which once activated, plays a role in several processes within the cell to restore energy homeostasis. The protein enhances catabolic pathways, such as β-oxidation and autophagy, to generate ATP, and inhibits anabo
  • PMID 25422142
  • Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications.
  • Nyandege AN1, Slattum PW1, Harpe SE2.
  • The Annals of pharmacotherapy.Ann Pharmacother.2015 Feb 9. pii: 1060028015569594. [Epub ahead of print]
  • OBJECTIVE: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy.DATA SOURCES: MEDLINE and CINAHL were searched for articles published in English through December 2014 using
  • PMID 25667198


  • C333H Ameliorated Insulin Resistance through Selectively Modulating Peroxisome Proliferator-Activated Receptor γ in Brown Adipose Tissue of db/db Mice
  • Zhang Ning,Chen Wei,Zhou Xinbo,Zhou Xiaolin,Xie Xinni,Meng Aimin,Li Song,Wang Lili
  • Biological and Pharmaceutical Bulletin 36(6), 980-987, 2013
  • … However, serious safety issues are associated with the PPARγ agonist thiazolidinediones (TZDs). …
  • NAID 130003361459
  • PPARγの近位尿細管におけるnon-genomic作用
  • 関 常司,遠藤 陽子
  • 内分泌・糖尿病・代謝内科 34(4), 353-356, 2012-04
  • NAID 40019328781
  • Peroxisome proliferator-activated receptor activity is involved in the osteoblastic differentiation regulated by bone morphogenetic proteins and tumor necrosis factor-α.
  • Takano Mariko,Otsuka Fumio,Matsumoto Yoshinori,Inagaki Kenichi,Takeda Masaya,Nakamura Eri,Tsukamoto Naoko,Miyoshi Tomoko,Sada Ken-ei,Makino Hirofumi
  • Molecular and Cellular Endocrinology 348(1), 224-232, 2012-01-02
  • … Recent studies have suggested possible adverse effects of thiazolidinediones on bone metabolism. …
  • NAID 120005232493


The thiazolidinediones also known as glitazones, are a class of medications used in the treatment of diabetes mellitus type 2. They were introduced in the late 1990s. Contents. 1 Mechanism of action. 1.1 PPARγ transactivation; 1.2 PPARγ ...
29 Jun 2011 ... Thiazolidinediones are also available in combination pills. Pioglitazone is combined with the biguanide medicine metformin (Actoplus Met) and sulfonylurea medicine glimepiride (Duetact). Rosiglitazone is combined with ...


 Thiazolidinediones and PPARγ agonistsThiazolidinediones andThiazolidinediones/ PPAR - Management Mechanism of action of thiazolidinediones thiazolidinediones glitazones increaseThiazolidinediones (TZDs)